Biotech News

Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions

Theravance Biopharma (TBPH)Theravance Biopharma2026-06-25 13:46 ESTClinical readout

Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in achieving $100

Open original release

Related news

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Present Data on Ampreloxetine at the 36th International Symposium on The Autonomic Nervous System

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma, Inc. Reports Third Quarter 2025 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Participate in Upcoming Investor Conferences

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma to Host Virtual KOL Investor Event to Review Ampreloxetine Phase 3 Clinical Development Program, Ahead of Topline Data in Q1 2026, on December 8, 2025

TBPHTheravance Biopharma2026-06-25 13:46 EST

Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

View all latest news

Theravance Biopharma

Theravance Biopharma is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.

Recent company news

TBPHTheravance Biopharma2026-06-26 08:46 EST

Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update

TBPHTheravance Biopharma2026-06-26 08:46 EST

Theravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment Conference

TBPHTheravance Biopharma2026-06-26 08:46 EST

Theravance Biopharma to Present New Analyses Highlighting YUPELRI® (revefenacin) Outcomes in COPD at the 2025 CHEST Annual Meeting

TBPHTheravance Biopharma2026-06-26 08:46 EST

Theravance Biopharma Launches Disease Education Campaign to Advance Scientific Understanding of Neurogenic Orthostatic Hypotension Due to Multiple System Atrophy

TBPHTheravance Biopharma2026-06-26 08:46 EST

Theravance Biopharma to Report Third Quarter 2025 Financial Results on November 10, 2025

Stock data

Close: —
Market cap: —
Exchange: NASDAQ
Sector: Biotechnology
Location: United States